Harbour Investments’s TherapeuticsMD TXMD Stock Holding History

Harbour Investments’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18	Hold	8	–	–	﹤0.01%	4725
2026 Q1	$16	Hold	8	–	–	﹤0.01%	4631
2025 Q4	$13	Hold	8	–	–	﹤0.01%	3836
2025 Q3	$9	Hold	8	–	–	﹤0.01%	3727
2025 Q2	$9	Hold	8	–	–	﹤0.01%	3587
2025 Q1	$7	Hold	8	–	–	﹤0.01%	3537
2024 Q4	$7	Hold	8	–	–	﹤0.01%	3475
2024 Q3	$13	Hold	8	–	–	﹤0.01%	3372
2024 Q2	$13	Hold	8	–	–	﹤0.01%	3268
2024 Q1	$18	Hold	8	–	–	﹤0.01%	3197
2023 Q4	$18	Hold	8	–	–	﹤0.01%	3110
2023 Q3	$24	Hold	8	–	–	﹤0.01%	2965
2023 Q2	$33	Hold	8	–	–	﹤0.01%	2992
2023 Q1	$30	Hold	8	–	–	﹤0.01%	2967
2022 Q4	$45	Hold	8	–	–	﹤0.01%	2961
2022 Q3	$0	Hold	8	–	–	﹤0.01%	2830
2022 Q2	$0	Buy	+8	New	+$76	﹤0.01%	2830
2021 Q4	$0	Sell	14 -15	-52%	-$450	﹤0.01%	3626
2021 Q3	$1K	Hold	29	–	–	﹤0.01%	3606
2021 Q2	$2K	Hold	29	–	–	﹤0.01%	3432
2021 Q1	$2K	Buy	+29	New	+$2.27K	﹤0.01%	3275

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Harbour Investments's TXMD Position: Q2 2026 in Review

Harbour Investments held its TherapeuticsMD (TXMD) position steady in Q2 2026 at 8 shares worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #4725.

Harbour Investments first reported a position in TXMD in Q1 2021 and has held it in 21 quarters since. The position peaked at $2K in Q2 2021. 44 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

Harbour Investments held 8 shares of TherapeuticsMD worth $18 as of Q2 2026.
Harbour Investments left its TherapeuticsMD share count unchanged in Q2 2026.
TherapeuticsMD made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4725 holding.
Harbour Investments first reported a position in TherapeuticsMD in Q1 2021 and has held it in 21 quarters since.
Harbour Investments's TherapeuticsMD position peaked at $2K in Q2 2021.
44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.